• Citer

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

par Harbeck, Nadia;Jassem, Jacek;Zhang, Qingyuan;Im, Young Hyuck;Wojtukiewicz, Marek;Sun, Qiang;Chen, Shin-Cheh;Goeldner, Rainer Georg;Uttenreuther-Fischer, Martina;Xu, Binghe;Piccart-Gebhart, Martine ;Huang, Chiun Sheng;Hurvitz, Sara;Yeh, Dah Cherng;Shao, Zhimin;Im, Seock Ah;Jung, Kyung Hae;Shen, Kunwei;Ro, Jungsil
Référence Lancet oncology, 17, 3, page (357-366)
Publication Publié, 2016-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
Auteur:	Harbeck, Nadia; Jassem, Jacek; Zhang, Qingyuan; Im, Young Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine; Huang, Chiun Sheng; Hurvitz, Sara; Yeh, Dah Cherng; Shao, Zhimin; Im, Seock Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil
Informations sur la publication:	Lancet oncology, 17, 3, page (357-366)
Statut de publication:	Publié, 2016-03
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(15)00540-9
	info:pii/S1470204515005409
	info:scp/84960496215